Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLA: Atezolizumab and Bevacizumab Combination in TNBC
NCT04739670Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Peter MacCallum Cancer Centre. Started Mar 2021; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04739670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739670.